Endostatins

01/01/2014 - "Endostatin is a potent anti-angiogenesis compound with efficacy in treating solid tumors and other diseases. "
02/01/2013 - "Furthermore, Ad-TERT p-E1 demonstrated significantly superior oncolytic effects in the RB mouse model, and Ad-endostatin effectively suppressed tumor growth and extended the overall lifespan of subjects; however, the Ad-E2F1 p-E1A was clearly less effective in attaining these goals. "
09/01/2008 - "High level of endostatin in epididymal epithelium: protection against primary malignancies in this organ?"
07/01/2000 - "A phase I trial of Endostatin which will evaluate the safety and efficacy of Endostatin at a range of doses in no more than 100 cancer patients has been initiated. "
05/01/2019 - "The anti-tumor effect of endostatin under IH condition is superior to that of the normoxia condition."

06/01/2018 - "A number of clinical studies have demonstrated the significant survival benefit of rh-endostatin in treating late stage non-small-cell lung carcinoma (NSCLC) and, as a result, rh-endostatin (Endostar®) was approved by the State Food and Drug Administration of China (CFDA) in September of 2005 as a treatment option for NSCLC. "
02/01/2006 - "[Randomized phase II trial on escalated doses of Rh-endostatin (YH-16) for advanced non-small cell lung cancer]."
08/20/2005 - "[Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients]."
12/20/2002 - "To study the relationship between expression of endostatin and clinical and pathophysiological characteristics in the non-small cell lung cancer (NSCLC). "
01/31/2023 - "Recombinant Endostatin as a Potential Radiosensitizer in the Treatment of Non-Small Cell Lung Cancer."

01/01/2010 - "Median endostatin concentration was significantly higher in patients with distant metastases than in patients with remission (141.95 v. 105.345 ng/ml, p < 0.05). "
01/01/2010 - "Although median serum endostatin levels are higher in patients with distant metastases than in patients with remission, its clinical usefulness is limited due to the overlapping data between the study groups. "
01/01/2010 - "We provided a cross-sectional analysis of the study group divided into patients with distant and/or locoregional metastases and patients with remission, and compared it with serum endostatin levels of healthy volunteers. "
05/01/2006 - "Endostatin has been shown to inhibit NPC growth, but its efficacy against NPC metastasis has not been shown in vivo. "
11/01/2007 - "This study was to evaluate the correlation of pretreatment serum endostatin level to posttreatment distant metastasis in patients with advanced NPC. "

01/01/2021 - "For patients with lung cancer, moderate to massive effusion, initial treatment, Karnofsky Performance Status (KPS) score ≥60, or anticipated survival time ≥3 months, Rh-endostatin (30-45 mg each time, once or twice a week 3-4 times) plus DDP (30-60 mg/m2) obtained a significant improvement in clinical response and a reduction of failure and progressive disease. "
11/01/2017 - "Our study confirmed that the CS nanoparticle is a feasible carrier for endostatin to be used in the treatment of lung cancer."
10/01/2005 - "The major goal of this study was to evaluate the combination of radiation and endostatin gene therapy in a preclinical lung cancer model. "
02/01/2018 - "Recombinant human endostatin (rh-ES), a mild inhibitor of angiogenesis, has been used for treating lung cancer. "
01/01/2018 - "Antiangiogenic effects of recombinant human endostatin in lung cancers."

07/01/2002 - "These findings indicate heterogeneity in the therapeutic efficacy of angiostatic molecules delivered by viral vectors and suggest that gene therapy with IFN-alpha(1) and endostatin might be useful for treatment of breast cancer."
01/01/2016 - "Endostatin inhibits the growth and migration of 4T1 mouse breast cancer cells by skewing macrophage polarity toward the M1 phenotype."
01/01/2013 - "Radiosensitization of breast cancer cells by TRAIL-endostatin-targeting gene therapy."
11/03/2010 - "To evaluate the antimetastatic potential of esVEGFR-2, gene therapy with vector expressing esVEGFR-2 (pesVEGFR-2) or endostatin (pEndo) as a positive control was conducted on murine metastatic mammary cancer. "
06/22/2007 - "The Endostatin 4349G > A polymorphism however does not appear to be associated with breast cancer susceptibility or severity in invasive disease. "